CTOs on the Move

Hoechst AG

www.hoechst.com

 
Hoechst AG is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

CareMount Medical

We have a number of positions available in our modern medical offices conveniently located at 90 and 110 South Bedford Road in Mount Kisco, as well as openings in our off-site offices in Yorktown, Katonah, Carmel, Fishkill, Poughkeepsie, Somers, Mahopa...

Youth Home

Youth Home, Inc. is a non-profit psychiatric treatment center located in Little Rock, Arkansas for emotionally troubled adolescents and their families.

CRB

CRB is a Oreland, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Novabay

We are passionate about improving people`s daily lives by offering clinically proven solutions to common skin and eye care problems through digital channels, traditional domestic retailers, and international distributors. We are in the process of growing from a small single-product company into a profitable mid-sized multi-product company. Our leading product, Avenova®, is the only lid & lash solution that brings eyes back to life by setting the highest standards of purity and efficacy. We pioneered the use of hypochlorous acid in the eyecare space and intend on making Avenova a household name. Our motto is, “If you have eyes, you need Avenova!” We also recently acquired DERMAdoctor, LLC, a skincare company offering more than 30 dermatologist-developed skincare products. We plan to launch nine new products this year with the founder of DERMAdoctor doing well known media placements such as QVC.

Adial Pharmaceuticals

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder (“AUD using our lead investigational new drug product, AD04. A Phase 2b University of Virginia investigator sponsored clinical trial of AD04 for the treatment of AUD showed promising results and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes.